SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2016
Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Fracture prevalence in thalassemia: a systematic review and meta-analysis.Archives of osteoporosis · 2021Pooled it
- Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.Blood advances · 2018Trial
- Factors Contributing to Improved Bone Mineral Density in Patients With Transfusion-Dependent Thalassemia.The Kaohsiung journal of medical sciences · 2026Article
- Baicalein Alleviates Iron Overload-Induced Ferroptosis and Osteogenic Blockade in Osteoblasts by Activating the Nrf2/GPX4 Pathway.BME frontiers · 2026Article
- Administration of green tea polyphenols mitigates iron-overload-induced bone loss in a β-thalassemia mouse model.NPJ science of food · 2025Article
- Aetiology, diagnosis and treatment of thalassemia-associated osteoporosis of the adult.Journal of endocrinological investigation · 2025Review
- Hypoparathyroidism in adults with iron overload diseases (IOD): evidence of a subclinical phenotype.Endocrine · 2025Article
- Ferroptosis and bone health: bridging the gap between mechanisms and therapy.Frontiers in immunology · 2025Review
- Iron and Bone Pathophysiology.Advances in experimental medicine and biology · 2025Review
- Trabecular bone score in the assessment of bone health in thalassemia major.Frontiers in endocrinology · 2025Article
- Lysosome-Iron-Mitochondria Axis in Osteoclasts: Iron as a Central Player.Research (Washington, D.C.) · 2025Review
- Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.Frontiers in endocrinology · 2025Article
- Bone and Joint Involvement in Beta Thalassemic Patients: A Cross-sectional Study.Indian journal of orthopaedics · 2025Article
- Depletion of macrophages and osteoclast precursors mitigates iron overload-mediated bone loss.IUBMB life · 2025Article
- Review
- Impact of genotype on multi-organ iron and complications in patients with non-transfusion-dependent β-thalassemia intermedia.Annals of hematology · 2024Article
- Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Decoding ferroptosis: transforming orthopedic disease management.Frontiers in pharmacology · 2024Review
- Current issues in evaluation and management of osteoporosis in Thailand.Osteoporosis and sarcopenia · 2023Review
- Fighting age-related orthopedic diseases: focusing on ferroptosis.Bone research · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thalassemia-associated osteoporosis constitutes a major complication in patients with thalassemia. This review presents the existing studies on the treatment of thalassemia-associated osteoporosis and discusses the management of this debilitating complication. A brief presentation of the disease characteristics and pathogenetic mechanisms is also provided. The life expectancy of patients with thalassemia has increased markedly in recent years resulting in the aging of the population and the emergence of new comorbidities. The majority of patients with thalassemia have low bone mineral density and experience lifelong fracture rates as high as 71 %. The pathogenesis of thalassemia-associated osteoporosis (TAO) is multifactorial with anemia and iron overload playing crucial role in its development. Data concerning the prevention and treatment of TAO are extremely limited. We performed a literature research in Pubmed and Scopus to identify interventional studies evaluating the effects of various agents on TAO. Seventeen studies were retrieved. We present the results of these studies as well as a brief overview of TAO including presentation, pathogenesis, and management. Most of the studies identified are of poor quality, are not randomized controlled, and include small number of participants. There are no data concerning effects on fracture rates. Bisphosphonates are the most widely studied agents and among them zoledronic acid is the most well studied. Hormone replacement treatment (HRT) shows beneficial but small effects. Denosumab and strontium ranelate have each been evaluated in only a single study, while there are no data about the effects of anabolic agents. Given the increased life expectancy and the increase in fracture rates with age, more data about the management of TAO are warranted. Moreover, due to the need for lifelong management starting at young age, careful treatment plans which may include sequential treatment may often be required. However, currently, there are no relevant data available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.